5 completed, 3 recruiting, 1 active not recruiting, 1 enrolling by invitation. 6 Not applicable, 3 Phase 1, 3 Phase 3, 2 Phase 2.
Follow 0.9 % saline: new trials by email Literature Review of 0.9 % saline trials Research Report on 0.9 % saline
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Hyperthermia Combined With Hydrogen Peroxide Microneedle Patch for Viral Warts 3% hydrogen peroxide solution, 0.9 % saline, Hyperthermia at 44℃ - Warts | Not applicable | Recruiting | First Hospital of China Medical University | 210 | 2026-05-01 | 2026-04-16 |
| Efficacy and Safety of Tranexamic Acid in Adult Liver Transplantation---ESTA Trial tranexamic acid, 0.9 % saline - Liver Transplantation, Tranexamic Acid | Not applicable | Recruiting | RenJi Hospital | 1546 | 2025-11-01 | 2025-12-08 |
| Study on Ketorolac for Improving Outcomes and Prognosis in Patients With Stanford Type A Aortic Dissection Ketorolac, 0.9 % saline - Aortic Dissection, Inflammation | Phase 3 | Recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 1346 | 2025-10-27 | 2026-08-31 |
| A Study on the Effects in Healthy People of a New Drug Called PDI204 for Treating COVID-19 PDI204, 0.9 % saline - COVID-19 Infection | Phase 1 | Active not recruiting | University of Melbourne | 32 | 2025-06-27 | 2026-05-05 |
| Effects of Esketamine on the Incidence of Postoperative Delirium and Postoperative Sleep Disturbance in Elderly Patients After Major Non-cardiac Surgery Esketamine, 0.9 % saline - Postoperative Delirium (POD), Postoperative Sleep Disturbance | Not applicable | Withdrawn | RenJi Hospital | 2025-04-01 | 2025-05-16 | |
| Preventive Effects of Silver Diamine Fluoride on Early Enamel Caries Silver diamine fluoride- potassium iodide, Fluoride varnish, 0.9 % saline - Demineralization, Tooth, White Spot Lesion of Tooth | Phase 2 | Not yet recruiting | National University of Malaysia | 99 | 2025-01-31 | 2025-01-30 |
| The Effectiveness of Allogenic Mesenchymal Stem Cells Therapy on Hair Regrowth in Androgenetic Alopecia. Mesenchymal Stem Cells, 0.9 % saline - Androgenetic Alopecia, Androgenetic Alopecia (AGA) | Phase 1 / Phase 2 | Enrolling by invitation | National Institute of Blood and Marrow Transplant (NIBMT), Pakistan | 70 | 2024-12-25 | 2025-01-08 |
| Ovarian Hyperstimulation Syndrome Using Calcium Infusion Calcium intravenous infsuion, 0.9 % saline - Ovarian Hyperstimulation Syndrome | Not applicable | Unknown | Al-Azhar University | 200 | 2022-03-01 | 2022-02-22 |
| Clinical Trial Comparing TaurolockTMHep100 (Taurolidine 1.35%) and 0.9% Saline As Prevention of Recurrent Catheter-related Bloodstream Infections TaurolockTMHep100, 0.9 % saline - Catheter Related Blood Stream Infections, Intestinal Failure | Not applicable | Completed | Copenhagen University Hospital, Rigshospitalet | 61 | 2019-06-03 | 2024-10-28 |
| Dexmedetomidine Dose-Dependent on Lung Function and AQP1 in One-Lung Ventilation Surgery dexmedetomidine 0.3 µg/kg/h, dexmedetomidine 0.5 µg/kg/h, 0.9 % saline - Acute Lung Injury(ALI) | Not applicable | Completed | People's Hospital of Guangxi Zhuang Autonomous Region | 60 | 2018-01-05 | 2025-08-28 |
| A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Iron-deficient Blood Donors Iron isomaltoside 1000 (Monofer®), Placebo - Iron-deficiency | Phase 3 | Completed | Pharmacosmos A/S | 107 | 2013-06-01 | 2018-03-15 |
| Calcium for Prevention of Ovarian Hyperstimulation Syndrome calcium, 0.9 % saline - Ovarian Hyperstimulation Syndrome | Phase 3 | Completed | Cairo University | 200 | 2011-10-01 | 2014-07-09 |
| Endothelin Receptor Antagonism in Proteinuric Nephropathy BQ-123 (selective endothelin A receptor antagonist), 0.9 % saline, Nifedipine - Chronic Kidney Disease, Proteinuria | Phase 1 | Completed | University of Edinburgh | 22 | 2006-05-01 | 2008-07-25 |
Ovarian Hyperstimulation Syndrome (2) · Acute Lung Injury (1) · Alopecia (1) · Anemia, Iron-Deficiency (1) · Aortic Dissection (1) · COVID-19 (1) · Cardiovascular Diseases (1) · Emergence Delirium (1) · End Stage Liver Disease (1) · Inflammation (1) · Intestinal Failure (1) · Proteinuria (1) · Renal Insufficiency, Chronic (1) · Tooth Demineralization (1) · Warts (1)
RenJi Hospital (2) · Al-Azhar University (1) · Cairo University (1) · Copenhagen University Hospital, Rigshospitalet (1) · First Hospital of China Medical University (1) · National Institute of Blood and Marrow Transplant (NIBMT), Pakistan (1) · National University of Malaysia (1) · People's Hospital of Guangxi Zhuang Autonomous Region (1) · Pharmacosmos A/S (1) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1) · University of Edinburgh (1) · University of Melbourne (1)
China (5) · Denmark (2) · Australia (1) · Egypt (1) · Malaysia (1) · Pakistan (1) · United Kingdom (1)
Ahmad Shuhud Irfani Zakaria, MClinDent (1) · David J Webb, MD (1) · DongJin Wang, MD (1) · Neeraj Dhaun, MBChB (1) · Stephen Kent, PhD, MD (1) · Tuo Pan, MD (1) · Waleed M El-Khayat, M.D. (1)
PMID 25552412, PMID 28576285, PMID 36454569, PMID 40554263, PMID 42235100